Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026)
Innoviva (INVA) reported Other Non-Current Liabilities of $1.1 million for Q1 2026, down 98.2% on a YoY basis from $62.0 million in Q1 2025, and little changed quarter-over-quarter from $1.1 million in Q4 2025.
Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Innoviva has reported Other Non-Current Liabilities for 13 years, with the latest figure at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 98.2% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 98.2% YoY), and the FY2025 full-year result was $1.1 million, down 97.9% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.1 million, roughly flat from $1.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $78.4 million in Q3 2022, with the low at $1.1 million in Q3 2024.
- Historically, Other Non-Current Liabilities has averaged $53.1 million across 5 years, with a median of $66.1 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 560050.0% — and 2024, when it plunged 98.37%.
- Innoviva's Other Non-Current Liabilities stood at $70.9 million in 2022, then decreased by 1.47% to $69.9 million in 2023, then decreased by 23.83% to $53.2 million in 2024, then sank by 97.9% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Innoviva | 1.69 Bn | 1.08 Bn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.12 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 56.53 Mn |
| Jun 30, 2025 | 55.15 Mn |
| Mar 31, 2025 | 62.01 Mn |
| Dec 31, 2024 | 53.23 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 69.87 Mn |
| Mar 31, 2024 | 71.69 Mn |
| Dec 31, 2023 | 69.88 Mn |
| Sep 30, 2023 | 66.14 Mn |
| Jun 30, 2023 | 68.58 Mn |
| Mar 31, 2023 | 70.13 Mn |
| Dec 31, 2022 | 70.92 Mn |
| Sep 30, 2022 | 78.42 Mn |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 45,000.00 |
| Mar 31, 2021 | 77,000.00 |
| Dec 31, 2020 | 106,000.00 |
| Sep 30, 2020 | 136,000.00 |